CVS Health Corporation (NYSE:CVS) reported its Q1 results, with EPS of $2.22 coming in better than the Street estimate of $2.15. Revenue was $76.8 billion, beating the Street estimate of $75.39 billion.
The top priority of the company’s strategy in Q1 seems to continue to focus on care delivery plans. It continues to be on the hunt for both clinic-based, home health and MSO assets to round its care delivery offering, though it acknowledges the challenging valuation environment.
Management acknowledged news of a pending transaction serves as an overhang on the company’s shares and its ability to deliver on its 2023 and 2024 earnings targets, however, it believes enough cash flow is generated to mitigate these moving pieces via share repurchase if it needs to, demonstrating some evidence of that this quarter.
The company expects the full 2022-year EPS to range from $8.20 to $8.40, compared to the consensus estimate of $8.27.
